Immunome, inc. IMNM.US Overview
BetaUS StockHealthcare
(No presentation for IMNM)
IMNM AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
IMNM Current Performance
-0.91%
Immunome, inc.
-0.35%
Avg of Sector
-0.22%
S&P500
IMNM Key Information
IMNM Financial Forecast
Unit : USD
IMNM Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.52 | -52.9% | -21.2% | 2.93M | 184.4% | 540.1% | -2,930.9% |
| 2024Q3 | -0.84 | -55.6% | 23.5% | 2.74M | -28.4% | -13% | -1,618.6% |
| 2024Q2 | -0.78 | -116.7% | 30% | 2.91M | -18.4% | -7.8% | -1,528% |
| 2024Q1 | -0.49 | - | 28.9% | 2.36M | - | -7.3% | -12,584.3% |
| 2023Q4 | -0.34 | - | -57.5% | 1.03M | - | -63.3% | -2,421.2% |
IMNM Profile
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.